In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease

Neurology

Volumn 52, Issue 4, 1999, Pages 691-699

  Kuhl, D E ^a,b   Koeppe, R A ^a   Minoshima, S ^a   Snyder, S E ^a   Ficaro, E P ^a   Foster, N L ^a   Frey, K A ^a   Kilbourn, M R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; PHYSOSTIGMINE; TRACER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG MONITORING; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TREATMENT PLANNING;

EID: 0033541026     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.4.691     Document Type: Article

References (40)

1. Davies P, Maloney AJR. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
2. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
3. Geula C, Mesulam M-M. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994.
4. Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 1994;21:801-808.
5. Irie T, Fukushi K, Namba H, et al. Brain acetylcholinesterase activity. Validation of a PET tracer in a rat model of Alzheimer's disease. J Nucl Med 1996;37:649-655.
6. 11C]PMP). Synapse 1996;22:123-131.
7. Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR. Mapping acetylcholinesterase in human brain using PET and N-[C-11]methylpiperidinyl propionate (PMP). J Nucl Med 1996;37(5):21P.
8. Iyo M, Namba H, Fukushi K, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997;349:1805-1809.
9. Namba H, Iyo M, Shinotoh H, Nagatsuka S, Fukushi K, Irie T. Preserved acetylcholinesterase activity in aged cerebral cortex. Lancet 1998;351:881-882.
10. Kuhl DE, Koeppe RA, Fessler JA, et al. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 1994;35:405-410.
11. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo imaging of cholinergic terminals in normal aging, Alzheimer's disease and Parkinson's disease. Ann Neurol 1996;40:399-410.
12. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
13. Folstein M, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
15. Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. Cerebrovasc Brain Metab Rev 1991;3:297-335.
16. Albin RL, Minoshima S, D'Amato C, Frey KA, Kuhl DA, Sima AAF. Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-466.
17. 11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998;25:751-754.
18. 125I-labeled cholinergic nerve marker (-)-5-iodobenzovesamicol. Nucl Med Biol 1993;20:929-937.
19. 11C]NMPB and PET: method development and differentiation of tracer delivery from receptor binding. J Cereb Blood Flow Metab 1998;18:619-631.
20. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187-198.
21. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme, 1988.
22. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomical standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528-1537.
23. Brummer ME, Mersereau RM, Eisner RL, Lewine RRJ. Automatic detection of brain contours in MRI data sets. IEEE Trans Med Imaging 1993;12:153-193.
24. Holthoff VA, Koeppe RA, Frey KA, Jewett D, Paradise A, Kuhl DE. Differentiation of radioligand delivery and binding in the brain: validation of a two-compartment model for [C-11]flumazenil. J Cereb Blood Flow Metab 1991;11:745-752.
25. Asthana S, Greig NH, Hegedus L, et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1995;58:299-309.
26. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986;47:263-277.
27. Reinikainen KJ, Reikkinen PJ, Paljarvi L, et al. Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data. Neurochem Res 1988;13:135-146.
28. Hara M, Minoshima S, Foster NL, Kuhl DE. Is regional cerebral blood flow coupled with glucose metabolism in Alzheimer's disease? J Nucl Med 1993;34(5):116P.
29. Somani SM, Khalique A. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. Drug Metab Disp 1987;15:5:627-633.
30. Pantano P, Baron JC, Lebrun-Grandie P, Duquesnoy N, Bousser M-G, Comar D. Regional cerebral blood flow and oxygen consumption in human aging. Stroke 1984;15:635-641.
31. Perry EK, Johnson M, Kerwin JM, et al. Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging 1992;13:393-400.
32. Decker MW. The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res Rev 1987;12:423-435.
33. Mesulam M-M, Geula C. Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex. Brain Res 1992;577: 112-120.
34. Bird TD, Stranahan S, Sumi SM, Raskind M. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983;14:284-293.
35. Gsell W, Strein I, Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm 1996;47(suppl):73-101.
36. Richardson PJ. Quantitation of cholinergic synaptosomes from guinea pig brain. J Neurochem 1981;37:258-260.
37. Sokoloff L. The relationship between function and energy metabolism: its use in the localization of functional activity in the nervous system. Neurosci Res Program Bull 1981;19:159-210.
38. Brun A, Gustafson L. Distribution of cerebral degeneration of Alzheimer's disease. A clinico-pathological study. Arch Psychiatr Nervenkr 1976;223:15-33.
39. Friedland RP, Brun A, Budinger TF. Pathological and PET correlations in Alzheimer's disease. Lancet 1985;1:228.
40. Moossy J, Zubenko GS, Martinez AJ, Rao GR, Kopp U, Hanin I. Lateralization of brain morphologic and cholinergic abnormalities in Alzheimer's disease. Arch Neurol 1989;46:639-642.